David Blake

1.2k total citations
33 papers, 843 citations indexed

About

David Blake is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, David Blake has authored 33 papers receiving a total of 843 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 12 papers in Molecular Biology and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in David Blake's work include Cancer-related Molecular Pathways (13 papers), Advanced Breast Cancer Therapies (10 papers) and Chronic Lymphocytic Leukemia Research (5 papers). David Blake is often cited by papers focused on Cancer-related Molecular Pathways (13 papers), Advanced Breast Cancer Therapies (10 papers) and Chronic Lymphocytic Leukemia Research (5 papers). David Blake collaborates with scholars based in United States, United Kingdom and Australia. David Blake's co-authors include Daniella Zheleva, Peter M. Fischer, David P. Lane, Nikolai Zhelev, Shudong Wang, Steven J. McClue, Jean Melville, Rosemary G. Clarke, Angela Cowan and Lesley I. McLellan and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

David Blake

30 papers receiving 825 citations

Peers

Countries citing papers authored by David Blake

Since Specialization

Citations

This map shows the geographic impact of David Blake's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Blake with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Blake more than expected).

Fields of papers citing papers by David Blake

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Blake. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Blake. The network helps show where David Blake may publish in the future.

Co-authorship network of co-authors of David Blake

This figure shows the co-authorship network connecting the top 25 collaborators of David Blake. A scholar is included among the top collaborators of David Blake based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Blake. David Blake is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy of fadraciclib (CYC065), a novel dual CDK2/9 inhibitor, on patient-derived models of colorectal cancer. 2024 ·Journal of Clinical Oncology ·(unknown), (unknown), (unknown), (unknown), (unknown), Shannon J. McCall, David Blake, Jason A. Somarelli, David S. Hsu	0
2	Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells 2022 ·Leukemia ·Rong Chen, Yuling Chen, Ping Xiong, Daniella Zheleva, David Blake, Michael J. Keating, William G. Wierda, William Plunkett	20
3	Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer 2020 ·PLoS ONE ·Sheelagh Frame, (unknown), Craig MacKay, Butrus Atrash, Peter Sheldrake, Edward McDonald, Paul A. Clarke, Paul Workman, David Blake, Daniella Zheleva	64
4	Reduced chronic pain: Another benefit of recovery at an inpatient rehabilitation facility over a skilled nursing facility? 2020 ·The American Journal of Surgery ·Juan P. Herrera‐Escobar, David Blake, (unknown), Kelsey Han, George Kasotakis, Haytham M.A. Kaafarani, George C. Velmahos, Adil H. Haider, Alí Salim, Deepika Nehra	1
5	Long-term social dysfunction after trauma: What is the prevalence, risk factors, and associated outcomes? 2019 ·Surgery ·Juan P. Herrera‐Escobar, (unknown), Michel Apoj, (unknown), (unknown), David Blake, Deepika Nehra, George C. Velmahos, Haytham M.A. Kaafarani, Alí Salim, Adil H. Haider, George Kasotakis	37
6	An Integrative “Omics” Approach, for Identification of Bona Fides PLK1 Associated Biomarker in Esophageal Adenocarcinoma 2019 ·Current Cancer Drug Targets ·Nousheen Bibi, (unknown), Judith Nicholson, (unknown), (unknown), David Blake, Ted R. Hupp	1
7	Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Patients with Relapsed or Refractory AML or MDS 2019 ·Blood ·Gautam Borthakur, Tapan M. Kadia, (unknown), Daniella Zheleva, David Blake, Judy H. Chiao	3
8	Abstract CT050: Expansion cohort of Phase I study of oral sapacitabine and oral seliciclib in patients with metastatic breast cancer and BRCA1/2 mutations 2019 ·Cancer Research ·Tanya E. Keenan, David Liu, Haitham Elmarakeby, Daniel G. Stover, Bose Kochupurakkal, Adam Tracy, (unknown), (unknown), Chelsea Andrews, Brendan Reardon, Beth Overmoyer, Eric P. Winer, Daniella Zheleva, Judy H. Chiao, David Blake, Eliezer M. Van Allen, Geoffrey I. Shapiro, Sara M. Tolaney	3
9	The Meisenheimer Complex as a Paradigm in Drug Discovery: Reversible Covalent Inhibition through C67 of the ATP Binding Site of PLK1 2018 ·Cell chemical biology ·Russell J. Pearson, David Blake, Mokdad Mezna, Peter M. Fischer, Nicholas J. Westwood, Campbell McInnes	11
10	Abstract 4178: The novel PLK1 inhibitor, CYC140: Identification of pharmacodynamic markers, sensitive target indications and potential combinations 2017 ·Cancer Research ·(unknown), Craig MacKay, (unknown), Elizabeth Pöhler, Karin Kroboth, Jonathan J. Hollick, Daniella Zheleva, Sheelagh Frame, David Blake	0
11	CYC065, potential therapeutic agent for AML and MLL leukaemia 2015 ·Clinical Lymphoma Myeloma & Leukemia ·Sheelagh Frame, (unknown), Susan L. Davis, David Blake, Daniella Zheleva	6
12	Abstract B182: Molecular basis for clinical development of the novel CDK2/9 inhibitor CYC065 in oncology 2015 ·Molecular Cancer Therapeutics ·(unknown), Sheelagh Frame, (unknown), Elizabeth Pöhler, Daniella Zheleva, David Blake	2
13	High Throughput Screens Yield Small Molecule Inhibitors of Leishmania CRK3:CYC6 Cyclin-Dependent Kinase 2011 ·PLoS neglected tropical diseases ·(unknown), Graeme Thomson, Kirk J. Malone, Matthew W. Nowicki, Elaine Brown, David Blake, Nicholas J. Turner, Malcolm D. Walkinshaw, Karen M. Grant, Jeremy C. Mottram	29
14	Abstract 3886: Therapeutic potential of CDK inhibitors in MLL leukemias 2010 ·Cancer Research ·Sheelagh Frame, (unknown), (unknown), David Blake, Simon R. Green, Daniella Zheleva	1
15	In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R‐roscovitine) 2002 ·International Journal of Cancer ·Steven J. McClue, David Blake, Rosemary G. Clarke, Angela Cowan, (unknown), Peter M. Fischer, (unknown), Jean Melville, (unknown), Shudong Wang, Nikolai Zhelev, Daniella Zheleva, David P. Lane	306
16	Regulation of γ-glutamylcysteine synthetase regulatory subunit (GLCLR) gene expression: identification of the major transcriptional start site in HT29 cells 1999 ·Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression ·(unknown), David Blake, Lesley I. McLellan	16
17	Overexpression of the regulatory subunit of γ-glutamylcysteine synthetase in HeLa cells increases γ-glutamylcysteine synthetase activity and confers drug resistance 1999 ·Biochemical Journal ·(unknown), David Blake, (unknown), Lesley I. McLellan	51
18	Overexpression of the regulatory subunit of γ-glutamylcysteine synthetase in HeLa cells increases γ-glutamylcysteine synthetase activity and confers drug resistance 1999 ·Biochemical Journal ·(unknown), David Blake, (unknown), Lesley I. McLellan	13
19	Regulation of human γ-glutamylcysteine synthetase: co-ordinate induction of the catalytic and regulatory subunits in HepG2 cells 1997 ·Biochemical Journal ·(unknown), David Blake, (unknown), (unknown)	103
20	Cooperative binding of Tn3 resolvase monomers to a functionally asymmetric binding site 1995 ·Current Biology ·David Blake, Martin R. Boocock, David J. Sherratt, W. Marshall Stark	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact